@article{ee2f0ed9b108477787be1219bd56fcd7,
title = "Wearable Devices Are Well Accepted by Patients in the Study and Management of Inflammatory Bowel Disease: A Survey Study",
abstract = "Background: Wearable devices are designed to capture health-related and physiological data. They may be able to improve inflammatory bowel disease management and address evolving research needs. Little is known about patient perceptions for their use in the study and management of inflammatory bowel disease. Aims: The aim of this survey study is to understand patient preferences and interest in wearable technology. Methods: Consecutive adult patients who self-reported having inflammatory bowel disease were approached at the Susan and Leonard Feinstein Inflammatory Bowel Disease Center at the Mount Sinai Hospital to complete a 28-question survey. Reponses were analyzed with descriptive statistics. The Pearson Chi-square test and Fischer{\textquoteright}s exact test were used to determine the association between demographic and disease-related features and survey responses. Results: Four hundred subjects completed the survey. 42.7% of subjects reported prior or current use of wearable devices. 89.0% of subjects believed that wearable devices can provide important information about their health, while 93.8% reported that they would use a wearable device if it could help their doctor manage their IBD. Subjects identified wrist-worn devices as the preferred device type and a willingness to wear these devices at least daily. Conclusions: Patients with inflammatory bowel disease believe that wearable devices can provide important information about their health and report a willingness to wear them frequently in research studies and as part the routine management of inflammatory bowel disease.",
keywords = "Crohn{\textquoteright}s disease, Inflammatory bowel disease, Survey, Ulcerative colitis, Wearable device",
author = "Hirten, {Robert P.} and Stephanie Stanley and Matteo Danieletto and Zachary Borman and Ari Grinspan and Prameela Rao and Jenny Sauk and Lin Chang and Bert Arnrich and Erwin Bӧttinger and Laurie Keefer and Sands, {Bruce E.}",
note = "Funding Information: RPH discloses consulting fees from HealthMode, Inc., and received research support from a Crohn{\textquoteright}s and Colitis Foundation Career Development Award (grant number 607934). BES discloses consulting fees from 4D Pharma, Abbvie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Boston Pharmaceuticals, Capella Biosciences, Celgene, Celltrion Healthcare, EnGene, Ferring, Genentech, Gilead, Hoffmann-La Roche, Immunic, Ironwood Pharmaceuticals, Janssen, Lilly, Lyndra, MedImmune, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer, Progenity, Prometheus Laboratories, Redhill Biopharma, Rheos Medicines, Seres Therapeutics, Shire, Synergy Pharmaceuticals, Takeda, Target PharmaSolutions, Theravance Biopharma R&D, TiGenix, Vivelix Pharmaceuticals; received honoraria for speaking in CME programs from Takeda, Janssen, Lilly, Gilead, Pfizer, Genetech; and received research funding from Celgene, Pfizer, Takeda, Theravance Biopharma R&D, Janssen. LK received research funds from Abbvie; is a consultant to Pfizer and Lucid Technologies; Equity ownership in MetaMe Health and Trellus Health. AG, SS, MD, ZB, PR, JS, LC, BA, and EB declare no conflicts of interest. Funding Information: This work was supported by a Crohn{\textquoteright}s and Colitis Foundation Career Development Award [Grant Number 607934] to RPH. Publisher Copyright: {\textcopyright} 2020, Springer Science+Business Media, LLC, part of Springer Nature.",
year = "2021",
month = jun,
doi = "10.1007/s10620-020-06493-y",
language = "English",
volume = "66",
pages = "1836--1844",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
number = "6",
}